Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Letter from Europe.
Gluck I. Gluck I. Buffalo Med J Mon Rev Med Surg Sci. 1857 Apr;12(11):698-702. Buffalo Med J Mon Rev Med Surg Sci. 1857. PMID: 35376728 Free PMC article. No abstract available.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators. Machiels JP, et al. Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29. Lancet Oncol. 2024. PMID: 38561010 Clinical Trial.
Nanoscale organization of the endogenous ASC speck.
Glück IM, Mathias GP, Strauss S, Rat V, Gialdini I, Ebert TS, Stafford C, Agam G, Manley S, Hornung V, Jungmann R, Sieben C, Lamb DC. Glück IM, et al. iScience. 2023 Nov 2;26(12):108382. doi: 10.1016/j.isci.2023.108382. eCollection 2023 Dec 15. iScience. 2023. PMID: 38047065 Free PMC article.
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma.
Haddad RI, Seiwert TY, Chow LQM, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Albright A, Mogg R, Ayers M, Huang L, Lunceford J, Cristescu R, Cheng J, Mehra R. Haddad RI, et al. Among authors: gluck i. J Immunother Cancer. 2022 Feb;10(2):e003026. doi: 10.1136/jitc-2021-003026. J Immunother Cancer. 2022. PMID: 35217573 Free PMC article.
Tumor Microenvironment in Oral Cancer Following Neoadjuvant Pembrolizumab: Preliminary Analysis of the Histopathologic Findings.
Dobriyan A, Gluck I, Alon E, Barshack I, Yahalom R, Vered M. Dobriyan A, et al. Among authors: gluck i. Front Oral Health. 2021 Apr 23;2:653104. doi: 10.3389/froh.2021.653104. eCollection 2021. Front Oral Health. 2021. Retraction in: Front Oral Health. 2022 Mar 22;3:893486. doi: 10.3389/froh.2022.893486. PMID: 35048002 Free PMC article. Retracted.
37 results